Spero Therapeutics (SPRO) Financial Statements & Analysis

Spero Therapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Spero Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Mar 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	59.62	47.98	103.78	48.58	3.07	18.26	9.33	18.15	3.97	1.98
Cost of Revenue	0.00	96.76	51.44	0.00	0.00	64.53	67.00	65.78	33.89	32.87
Gross Profit	59.62	-48.78	52.34	48.58	3.07	18.26	-57.67	-47.63	-29.92	-30.89
Operating Expenses
Research & Development	38.47	96.76	51.44	47.59	64.53	64.53	69.40	67.88	33.89	32.87
Selling, General & Administrative	21.18	23.70	25.55	36.48	41.70	41.70	21.44	15.59	12.89	10.84
Operating Expenses	52.46	24.58	30.86	90.78	91.04	106.23	21.44	15.59	42.81	41.73
Operating Income	7.16	-73.36	21.48	-42.20	-87.97	-87.97	-79.11	-63.22	-42.81	-41.73
Other Income/Expense
Interest Income	2.51	4.74	3.94	1.11	0.35	0.35	0.40	1.33	1.14	0.30
Interest Expense	0.00	0.00	0.00	2.61	1.94	-1.94	0.00	0.00	0.30	0.30
Other Income/Expense	-0.84	4.80	3.92	-4.22	-1.79	-1.79	0.83	2.29	1.14	1.84
Income
Income Before Tax	8.83	-68.57	25.40	-46.42	-89.76	-89.76	-78.28	-60.93	-41.66	-46.10
Income Tax Expense	0.26	0.00	2.60	0.00	0.00	-	0.00	0.00	0.00	-0.36
Net Income	8.57	-68.57	22.81	-46.42	-89.76	-89.76	-78.28	-60.93	-41.66	-46.10
Net Income - Continuous Operations	8.57	-68.57	22.81	-46.42	-89.76	-89.76	-78.28	-60.93	-41.66	-46.10
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-	-
EBITDA	7.16	-72.48	27.15	-42.94	-87.17	-87.33	-78.35	-62.47	-42.40	-41.37
EBIT	7.16	-72.48	26.79	-43.81	-	-87.97	-79.11	-	-	-
Depreciation & Amortization	0.00	0.00	0.37	0.87	0.65	0.65	0.76	0.75	0.41	0.36
Earnings Per Share
Basic EPS	-	-1.00	-	-1.00	-3.00	-3.00	-4.00	-3.00	-3.00	-18.00
Diluted EPS	-	-1.00	-	-1.00	-3.00	-3.00	-4.00	-3.00	-3.00	-18.00
Basic Shares Outstanding	56.02	54.04	52.70	37.59	30.90	30.90	22.39	18.16	16.00	2.59
Diluted Shares Outstanding	59.04	54.04	52.99	37.59	30.90	30.90	22.39	18.16	16.00	2.59

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Spero Therapeutics Financial Statements

What was Spero Therapeutics's revenue in fiscal 2025?

Spero Therapeutics reported revenue of $59.62M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 24.3% from $47.98M a year earlier.

Is Spero Therapeutics profitable?

Yes. Spero Therapeutics earned net income of $8.57M in fiscal 2025, a net margin of 14.4%. In fiscal 2024 it lost $68.57M.

What is Spero Therapeutics's operating margin?

Spero Therapeutics's operating income was $7.16M on revenue of $59.62M in fiscal 2025, an operating margin of 12.0%, compared with -152.9% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition